Biologics Safety Testing Market Share, Industry Analysis, Scope, Research Report 2022-2030

Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: May 2022 Report ID: BIOT2222 Pages: 1 - 223 Formats*:     
Category : Biotechnology
The global Biologics Safety Testing Market Overview:

According to SPER Market Research, the Biologics Safety Testing Market is estimated to reach USD 8.56 billion by 2030 with a CAGR of 10.8%. The expansion of the biologics and biosimilars markets, increasing concerns over cell culture contamination, and rising biopharmaceuticals research & development activities and investments, emerging markets, and growing biopharmaceutical outsourcing; are the key driver for the escalation of the market.
Impact of COVID-19 on the Biologics Safety Testing Market 
To provide biologics safety testing for developing safety test kits, manufacturing of vaccines testing to treat and target the infection. Pharmaceutical and biopharmaceutical companies and the biologics safety testing market have taken steps toward research in biologics safety testing.

Scope of the report:
 Report Metric Details
 Market size available for years 2019-2030
 Base year considered 2021
 Forecast period 2022-2030
 Segments coveredBy Product, By Application, By End-User, By Region
 Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
 Companies Covered
Agilent Technologies, Inc., Almac Group, Associates of Cape Cod, Inc. BioMérieux SA, Bio-Rad Laboratories, Inc., Charles River Laboratories, Inc., Lonza, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fujifilm Wako Pure Chemical Corporation, Maravai Lifesciences, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories, LLC, Pacific BioLabs, PromoCell GmbH, Sartorius AG, SGS SA, Thermo Fisher Scientific, Inc., WuXi AppTec.

Driver: expansion in the biosimilars and biologics markets
Heavy investments in the development of biologics and biosimilars by big companies. Growth in the biosimilars and biologics markets, Growing concerns over cell culture contamination, rising biopharmaceuticals R&D activities and investments; are the key factors, which drive the market expansion.

Opportunity: Emerging markets offer profitable opportunities
Emerging markets offer rewarding opportunities, and growing biopharmaceutical outsourcing; will provide enormous opportunities in the Biologics Safety Testing Market.

Challenges:  lack of skilled professionals
Lack of skilled personnel to handle the advanced technologies and the development of new and improved safety testing. 

Global Biologics Safety Testing Market Segmentation:

By Product & Service: Based on the Product & Service, Global Biologics Safety Testing Market is segmented as; Consumables, Instrument, and Services.

By Application: Based on the Application, Global Biologics Safety Testing Market is segmented as; Blood and Blood Products Manufacturing, Cellular & Gene Therapy Products Manufacturing, Monoclonal Antibodies Manufacturing, and Vaccine Manufacturing.
By Test Type: Based on the Test Type, Global Biologics Safety Testing Market is segmented into; Bioburden Tests, Endotoxin tests, Mycoplasma Tests, Residual Host-cell Proteins & DNA Detection Tests, Sterility tests, and Virus safety tests.

By Region: North America dominates the biggest share of the market; this is due to the increasing academic and government investments, quick expansion in the biopharmaceutical industry, growing demand for high-quality research tools for data reproducibility, and growing alertness among consumers about product safety.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Biologics Safety Testing Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Biologics Safety Testing Market, By Product & Service, 2019-2030 (USD Million)
6.1. Consumables
6.2. Instrument
6.3. Services

7. Global Biologics Safety Testing Market, By Application, 2019-2030 (USD Million)
7.1. Blood and Blood Products Manufacturing
7.2. Cellular & Gene Therapy Products Manufacturing
7.3. Monoclonal Antibodies Manufacturing
7.4. Other Application
7.5. Vaccine Manufacturing

8. Global Biologics Safety Testing Market, By Test Type , 2019-2030 (USD Million)
8.1. Bioburden Tests
8.2. Endotoxin Test
8.3. Mycoplasma Tests
8.4. Residual Host-cell Proteins & DNA Detection Tests
8.5. Sterility Test
8.6. Virus safety Test

9. Global Biologics Safety Testing Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia 
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles
10.1. Agilent Technologies, Inc. 
10.1.1. Company details 
10.1.2. Financial outlook
10.1.3. Product summary 
10.1.4. Recent developments
10.2. Almac Group 
10.2.1. Company details 
10.2.2. Financial outlook
10.2.3. Product summary 
10.2.4. Recent developments
10.3. Associates of Cape Cod, Inc. 
10.3.1. Company details 
10.3.2. Financial outlook
10.3.3. Product summary 
10.3.4. Recent developments
10.4. BioMérieux SA 
10.4.1. Company details 
10.4.2. Financial outlook
10.4.3. Product summary 
10.4.4. Recent developments
10.5. Bio-Rad Laboratories, Inc. 
10.5.1. Company details 
10.5.2. Financial outlook
10.5.3. Product summary 
10.5.4. Recent developments
10.6. Charles River Laboratories, Inc. Lonza 
10.6.1. Company details 
10.6.2. Financial outlook
10.6.3. Product summary 
10.6.4. Recent developments
10.7. Eurofins Scientific 
10.7.1. Company details 
10.7.2. Financial outlook
10.7.3. Product summary 
10.7.4. Recent developments
10.8. F. Hoffmann-La Roche Ltd.
10.8.1. Company details 
10.8.2. Financial outlook
10.8.3. Product summary 
10.8.4. Recent developments
10.9. Fujifilm Wako Pure Chemical Corporation
10.9.1. Company details 
10.9.2. Financial outlook
10.9.3. Product summary 
10.9.4. Recent developments
10.10. Maravai Lifesciences 
10.10.1. Company details 
10.10.2. Financial outlook
10.10.3. Product summary 
10.10.4. Recent developments
10.11. Merck KGaA
10.11.1. Company details 
10.11.2. Financial outlook
10.11.3. Product summary 
10.11.4. Recent developments
10.12. Microcoat Biotechnologie GmbH
10.12.1. Company details 
10.12.2. Financial outlook
10.12.3. Product summary 
10.12.4. Recent developments
10.13. Nelson Laboratories, LLC 
10.13.1. Company details 
10.13.2. Financial outlook
10.13.3. Product summary 
10.13.4. Recent developments
10.14. Pacific BioLabs 
10.14.1. Company details 
10.14.2. Financial outlook
10.14.3. Product summary 
10.14.4. Recent developments
10.15. PromoCell GmbH 
10.15.1. Company details 
10.15.2. Financial outlook
10.15.3. Product summary 
10.15.4. Recent developments
10.16. QIAGEN 
10.16.1. Company details 
10.16.2. Financial outlook
10.16.3. Product summary 
10.16.4. Recent developments
10.17. Sartorius AG 
10.17.1. Company details 
10.17.2. Financial outlook
10.17.3. Product summary 
10.17.4. Recent developments
10.18. SGS SA 
10.18.1. Company details 
10.18.2. Financial outlook
10.18.3. Product summary 
10.18.4. Recent developments
10.19. Thermo Fisher Scientific, Inc. 
10.19.1. Company details 
10.19.2. Financial outlook
10.19.3. Product summary 
10.19.4. Recent developments
10.20. WuXi AppTec 
10.21.1. Company details 
10.21.2. Financial outlook
10.21.3. Product summary 
10.21.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.




Not able to find what you are looking for? Need customization in the existing report?
Click Here
  • 15% off
    $ 4250
  • 20% off
    $ 6400
  • 25% off
    $ 7450
Pre-Purchase Inquiry
Request Customization
100% Secure Payment

SPER American Express
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us